Key result
Human IGFBP-1 administration for 14 days had no effect on increased kidney weight or albuminuria in early diabetes in mice, although it abolished renal cortical IGF-I accumulation.
Why the study?
Does hIGFBP-1 administration prevent early diabetic renal changes in STZ-induced diabetic mice?
Does hIGFBP-1 administration prevent early diabetic renal changes in STZ-induced diabetic mice?
Administration of hIGFBP-1 in diabetic mice does not prevent early diabetic renal hypertrophy or albuminuria, challenging the hypothesis that IGFBP-1 plays a major role in early diabetic renal changes.
Answers are grounded in this paper and cite their sources.
hIGFBP-1 does not prevent early diabetic renal changes in mice; challenges its hypothesized role and leaves therapeutic targets open.
Insulin-like growth factor I (IGF-I) accumulates in the kidney following the onset of diabetes, initiating diabetic renal hypertrophy. Increased renal IGF-I protein content, which is not reflected in messenger RNA (mRNA) levels, suggests that renal IGF-I accumulation is due to sequestration of circulating IGF-I rather than to local synthesis. It has been suggested that IGF-I is trapped in the kidney by IGF binding protein 1 (IGFBP-1). We administered purified human IGFBP-1 (hIGFBP-1) to nondiabetic and diabetic mice as three daily sc injections for 14 days, starting 6 days after induction of streptozotocin diabetes when the animals were overtly diabetic. Markers of early diabetic renal changes (i.e., increased kidney weight, glomerular volume, and albuminuria) coincided with accumulation of renal cortical IGF-I despite decreased mRNA levels in 20-day diabetic mice. Human IGFBP-1 administration had no effect on increased kidney weight or albuminuria in early diabetes, although it abolished renal cortical IGF-I accumulation and glomerular hypertrophy in diabetic mice. Increased IGF-I levels in kidneys of normal mice receiving hIGFBP-1 were not reflected on kidney parameters. IGFBP-1 administration in diabetic mice had only minor effects on diabetic renal changes. Accordingly, these results did not support the hypothesis that IGFBP-1 plays a major role in early renal changes in diabetes.
No takes yet. Share an insight, caveat, or question.
Cingel-Ristić et al. (2005) studied Streptozotocin-induced diabetes (n=50). Human Insulin-Like Growth Factor Binding Protein-1 (hIGFBP-1) vs. Placebo (0.154 M NaCl) was evaluated on Kidney weight and albuminuria. Human IGFBP-1 administration for 14 days had no effect on increased kidney weight or albuminuria in early diabetes in mice, although it abolished renal cortical IGF-I accumulation.
Synapse has enriched 10 related papers. Consider them for comparative context: